CN109906232B - 包含λ轻链和κ轻链的多特异性抗体分子 - Google Patents

包含λ轻链和κ轻链的多特异性抗体分子 Download PDF

Info

Publication number
CN109906232B
CN109906232B CN201780067185.XA CN201780067185A CN109906232B CN 109906232 B CN109906232 B CN 109906232B CN 201780067185 A CN201780067185 A CN 201780067185A CN 109906232 B CN109906232 B CN 109906232B
Authority
CN
China
Prior art keywords
seq
antibody molecule
antigen
sequence
hcp2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780067185.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN109906232A (zh
Inventor
A.洛夫
B.E.瓦什
S.J.迈奥科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marengo Treatment Co
Marengo Therapeutics Inc
Original Assignee
Marengo Treatment Co
Elstar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marengo Treatment Co, Elstar Therapeutics Inc filed Critical Marengo Treatment Co
Priority to CN202311356042.4A priority Critical patent/CN118005799A/zh
Publication of CN109906232A publication Critical patent/CN109906232A/zh
Application granted granted Critical
Publication of CN109906232B publication Critical patent/CN109906232B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780067185.XA 2016-09-23 2017-09-22 包含λ轻链和κ轻链的多特异性抗体分子 Active CN109906232B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311356042.4A CN118005799A (zh) 2016-09-23 2017-09-22 包含λ轻链和κ轻链的多特异性抗体分子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662399319P 2016-09-23 2016-09-23
US62/399,319 2016-09-23
US201762474569P 2017-03-21 2017-03-21
US62/474,569 2017-03-21
PCT/US2017/053053 WO2018057955A1 (en) 2016-09-23 2017-09-22 Multispecific antibody molecules comprising lambda and kappa light chains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311356042.4A Division CN118005799A (zh) 2016-09-23 2017-09-22 包含λ轻链和κ轻链的多特异性抗体分子

Publications (2)

Publication Number Publication Date
CN109906232A CN109906232A (zh) 2019-06-18
CN109906232B true CN109906232B (zh) 2023-11-07

Family

ID=60043296

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780067185.XA Active CN109906232B (zh) 2016-09-23 2017-09-22 包含λ轻链和κ轻链的多特异性抗体分子
CN202311356042.4A Pending CN118005799A (zh) 2016-09-23 2017-09-22 包含λ轻链和κ轻链的多特异性抗体分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311356042.4A Pending CN118005799A (zh) 2016-09-23 2017-09-22 包含λ轻链和κ轻链的多特异性抗体分子

Country Status (7)

Country Link
US (2) US11673971B2 (https=)
EP (1) EP3515936A1 (https=)
JP (1) JP7274413B2 (https=)
CN (2) CN109906232B (https=)
AU (1) AU2017331277B2 (https=)
CA (1) CA3036564A1 (https=)
WO (1) WO2018057955A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
EP2925785A4 (en) 2012-11-28 2016-11-16 Zymeworks Inc MANIPULATED IMMUNOGLOBULIN HEAVY CHAIN LIGHT CHAIN COUPLES AND USES THEREOF
AU2016334063B2 (en) 2015-10-08 2023-05-25 Zymeworks Bc Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
CN109906232B (zh) 2016-09-23 2023-11-07 马伦戈治疗公司 包含λ轻链和κ轻链的多特异性抗体分子
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
CA3059769A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN112236448B (zh) * 2018-04-17 2025-02-11 海德堡生物技术有限公司 用包含NC-1-Fc的蛋白寡聚体治疗血管发生、纤维化和癌症相关疾病的手段和方法
CA3099308A1 (en) * 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
WO2020172601A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
CN110428870B (zh) * 2019-08-08 2023-03-21 苏州泓迅生物科技股份有限公司 一种预测抗体重链轻链配对概率的方法及其应用
JP7650047B2 (ja) * 2019-11-27 2025-03-24 株式会社 MiyaCare Therapeutics 変異型結合性タンパク質の製造方法及び変異型ｐｄ－１
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
EP4069294A4 (en) * 2019-12-02 2024-07-10 Dana-Farber Cancer Institute, Inc. Antibodies against pd-l1 and methods of use thereof
CN112898427B (zh) * 2019-12-03 2023-06-30 同济大学苏州研究院 一种抗c-Met单臂抗体及其制备方法和应用
CN111018969A (zh) * 2019-12-27 2020-04-17 上海药明生物技术有限公司 采用轻链select联合层析色谱纯化双特异性抗体的方法
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
CA3190755A1 (en) 2020-08-26 2022-03-03 Andreas Loew Multifunctional molecules that bind to calreticulin and uses thereof
US20230391881A1 (en) * 2020-10-14 2023-12-07 University Of Virginia Patent Foundation Compositions and methods for overcoming dr5-induced immune evasion by solid tumors
JP2023549257A (ja) 2020-11-18 2023-11-22 ノバルティス アーゲー Ｎｌｒｃ４－ｇｏｆインフラマソーム病の処置における使用のための二特異性抗体
ES2967381T3 (es) 2020-12-18 2024-04-30 Lamkap Bio Beta Ag Anticuerpos biespecíficos contra CEACAM5 y CD47
US20240084012A1 (en) * 2020-12-31 2024-03-14 Abvision, Inc. Anti-pd-1/cd47 bispecific antibody and use thereof
EP4281484B1 (en) * 2021-01-22 2026-03-18 Hangzhou Baikai Biopharmaceutical Co., Ltd Anti-her-2/trop-2 constructs and uses thereof
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
US20240218065A1 (en) * 2021-06-15 2024-07-04 Shenghe (China) Biopharmaceutical Co. Multispecific antigen-binding protein and use thereof
US20240327543A1 (en) * 2021-08-02 2024-10-03 Shenghe (China) Biopharmaceutical Co., Ltd. Multispecific antigen-binding protein and use thereof
US20240404634A1 (en) * 2021-08-31 2024-12-05 Just-Evotec Biologics, Inc. Residual artificial neural network to generate protein sequences
US20250230256A1 (en) 2022-06-16 2025-07-17 Lamkap Bio Beta Ltd Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
CN119948063A (zh) * 2022-06-23 2025-05-06 信达生物制药(苏州)有限公司 结合egfr和b7-h3的双特异性抗体
TW202506726A (zh) * 2023-04-07 2025-02-16 美商麥迪紐有限責任公司 雙特異性工程化抗體
WO2025250941A1 (en) * 2024-05-31 2025-12-04 Dna Twopointo Inc. Cμ4 REGION FOR PAIRING HEAVY AND LIGHT CHAINS IN MULTI-SPECIFIC ANTIBODIES
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127655A1 (en) * 2007-04-13 2008-10-23 Biogen Idec Ma Inc. Anti-alpha 6 beta 4 integrin antibodies and uses therof
WO2010054010A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
CN102858800A (zh) * 2010-01-04 2013-01-02 阿尔金-X公司 人源化抗体
CN103261220A (zh) * 2010-08-16 2013-08-21 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
CN104011221A (zh) * 2011-12-20 2014-08-27 米迪缪尼有限公司 用于双特异性抗体支架的经修饰的多肽
CN104704004A (zh) * 2012-10-08 2015-06-10 罗切格利卡特公司 包含两个Fab片段的无Fc的抗体及使用方法
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
CN105612182A (zh) * 2013-10-11 2016-05-25 豪夫迈·罗氏有限公司 多特异性结构域交换共有可变轻链抗体

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4617447A (en) 1985-03-01 1986-10-14 Caterpillar Inc. Drive assembly for drawing a movable welding carriage and method of welding
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5731116A (en) 1989-05-17 1998-03-24 Dai Nippon Printing Co., Ltd. Electrostatic information recording medium and electrostatic information recording and reproducing method
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
SI2168984T1 (sl) * 1999-03-25 2012-12-31 Abbott Gmbh & Co. Kg Človeška protitelesa za vezavo IL-12 in postopki izdelave
WO2000060070A1 (en) 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
AU2003209272A1 (en) 2002-01-16 2003-09-02 Zyomyx, Inc. Engineered binding proteins
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
EP1773885B1 (en) 2004-08-05 2010-04-21 Genentech, Inc. Humanized anti-cmet antagonists
CA2602663A1 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
US7943873B2 (en) 2008-04-15 2011-05-17 General Electric Company Circuit breaker with locking mechanism
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
EP2635602B1 (en) * 2010-11-03 2016-09-07 Argen-X Nv Anti c-met antibodies
EP2768857B1 (en) * 2011-10-19 2020-01-01 NovImmune SA Methods of purifying antibodies
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
AU2016334063B2 (en) 2015-10-08 2023-05-25 Zymeworks Bc Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CN109906232B (zh) 2016-09-23 2023-11-07 马伦戈治疗公司 包含λ轻链和κ轻链的多特异性抗体分子

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127655A1 (en) * 2007-04-13 2008-10-23 Biogen Idec Ma Inc. Anti-alpha 6 beta 4 integrin antibodies and uses therof
WO2010054010A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
CN102858800A (zh) * 2010-01-04 2013-01-02 阿尔金-X公司 人源化抗体
CN103261220A (zh) * 2010-08-16 2013-08-21 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
CN104011221A (zh) * 2011-12-20 2014-08-27 米迪缪尼有限公司 用于双特异性抗体支架的经修饰的多肽
CN104704004A (zh) * 2012-10-08 2015-06-10 罗切格利卡特公司 包含两个Fab片段的无Fc的抗体及使用方法
CN105612182A (zh) * 2013-10-11 2016-05-25 豪夫迈·罗氏有限公司 多特异性结构域交换共有可变轻链抗体
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Comparing domain interactions within antibody Fabs with kappa and lambda light chains;Raheleh Toughiri等;《mAbs》;20160725;第8卷(第7期);第1276-1285页 *
Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG;Nicolas Fischer等;《Nature Communications》;20150212;第6卷(第12期);第1-12页 *
Germline VH/VL pairing in antibodies;Narayan Jayaram等;《Protein Engineering, Design & Selection》;20120715;第25卷(第10期);第523-529页 *
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies;Christian Klein等;mAbs;第4卷(第6期);653-663 *
World Bispeci!c Antibody Summit，September 27–28, 2011, Boston, MA;Eugen Dhimolea等;《mAbs 》;20120101;第4卷(第1期);第4-13页 *
抗体分子内不配对半胱氨酸的研究进展;王辉等;中国生物制品学杂志;第28卷(第8期);880-882 *

Also Published As

Publication number Publication date
US20230272119A1 (en) 2023-08-31
JP2019531725A (ja) 2019-11-07
EP3515936A1 (en) 2019-07-31
AU2017331277A1 (en) 2019-03-28
JP7274413B2 (ja) 2023-05-16
WO2018057955A1 (en) 2018-03-29
US11673971B2 (en) 2023-06-13
US20190218311A1 (en) 2019-07-18
CN109906232A (zh) 2019-06-18
CN118005799A (zh) 2024-05-10
CA3036564A1 (en) 2018-03-29
AU2017331277B2 (en) 2024-05-30
US12421323B2 (en) 2025-09-23

Similar Documents

Publication Publication Date Title
CN109906232B (zh) 包含λ轻链和κ轻链的多特异性抗体分子
US20220288200A1 (en) Multispecific and multifunctional molecules and uses thereof
JP7554742B2 (ja) 抗ｔｃｒ抗体分子およびその使用
CN114026122B (zh) 结合t细胞相关癌细胞的多功能分子及其用途
AU2018260545B2 (en) Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
JP2023100868A (ja) 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
US20200291089A1 (en) Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2019113464A1 (en) Multispecific molecules and uses thereof
CN114127113A (zh) 与钙网蛋白结合的多功能分子及其用途
CN116234829A (zh) 抗tcr抗体分子及其用途
CN116761818A (zh) 检测trbc1或trbc2的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: Marengo treatment Co.

Address before: Massachusetts, USA

Applicant before: Elstar Therapeutics, Inc.

GR01 Patent grant
GR01 Patent grant